Literature DB >> 10933928

Transduction of human PBMC-derived dendritic cells and macrophages by an HIV-1-based lentiviral vector system.

R Schroers1, I Sinha, H Segall, I G Schmidt-Wolf, C M Rooney, M K Brenner, R E Sutton, S Y Chen.   

Abstract

Professional antigen-presenting cells, such as dendritic cells (DCs) and macrophages, are target cells for gene therapy of infectious disease and cancer. However, transduction of DCs and macrophages has proved difficult by most currently available gene transfer methods. Several recent studies have shown that lentiviral vector systems can efficiently transduce many nondividing and differentiated cell types. In this study, we examined the gene transfer to DCs and macrophages using a lentiviral vector system. Human DCs were propagated from the adherent fraction of peripheral blood mononuclear cells (PBMCs) by culture in medium containing GM-CSF, IL-4, and TNF-alpha. Human macrophages were propagated from adherent PBMCs in medium containing GM-CSF. High titers of a replication-defective vesicular stomatitis virus glycoprotein G pseudotyped HIV-1-based vector encoding the enhanced yellow fluorescent protein were produced. In immature DCs (culture days 3 and 5), transduction efficiencies of 25 to 35% were achieved at a multiplicity of infection of 100. However, the transduction efficiency was decreased in more mature DCs (culture day 8 or later). Furthermore, monocyte-derived macrophages were also transduced by the lentiviral vector system. In addition, Alu-LTR PCR demonstrated the integration of the HIV-1 provirus into the cellular genome of the transduced DCs and macrophages. Allogeneic mixed lymphocyte reactions revealed similar antigen-presenting functions of untransduced and lentivirally transduced DCs. Thus, the results of this study demonstrate that both PBMC-derived DCs and macrophages can be transduced by lentiviral vectors.

Entities:  

Mesh:

Year:  2000        PMID: 10933928     DOI: 10.1006/mthe.2000.0027

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  31 in total

1.  Postentry restriction to human immunodeficiency virus-based vector transduction in human monocytes.

Authors:  S Neil; F Martin; Y Ikeda; M Collins
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

Review 2.  Immunization delivered by lentiviral vectors for cancer and infectious diseases.

Authors:  Biliang Hu; April Tai; Pin Wang
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

3.  Tubulovesicular structures within vesicular stomatitis virus G protein-pseudotyped lentiviral vector preparations carry DNA and stimulate antiviral responses via Toll-like receptor 9.

Authors:  Andreas Pichlmair; Sandra S Diebold; Stephen Gschmeissner; Yasuhiro Takeuchi; Yasuhiro Ikeda; Mary K Collins; Caetano Reis e Sousa
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

4.  Programming the next generation of dendritic cells.

Authors:  Richard G Carroll; Carl H June
Journal:  Mol Ther       Date:  2007-05       Impact factor: 11.454

Review 5.  Lentivirus as a potent and mechanistically distinct vector for genetic immunization.

Authors:  Yukai He; Louis D Falo
Journal:  Curr Opin Mol Ther       Date:  2007-10

Review 6.  Directing dendritic cell immunotherapy towards successful cancer treatment.

Authors:  Rachel Lubong Sabado; Nina Bhardwaj
Journal:  Immunotherapy       Date:  2010-01       Impact factor: 4.196

Review 7.  Recombinant lentivector as a genetic immunization vehicle for antitumor immunity.

Authors:  Yukai He; David Munn; Louis D Falo
Journal:  Expert Rev Vaccines       Date:  2007-12       Impact factor: 5.217

8.  Transduction of human antigen-presenting cells with integrase-defective lentiviral vector enables functional expansion of primed antigen-specific CD8(+) T cells.

Authors:  Donatella R M Negri; Roberta Bona; Zuleika Michelini; Pasqualina Leone; Iole Macchia; Mary E Klotman; Mirella Salvatore; Andrea Cara
Journal:  Hum Gene Ther       Date:  2010-08       Impact factor: 5.695

9.  An effective cancer vaccine modality: lentiviral modification of dendritic cells expressing multiple cancer-specific antigens.

Authors:  Bei Wang; Jin He; Chen Liu; Lung-Ji Chang
Journal:  Vaccine       Date:  2006-02-28       Impact factor: 3.641

10.  Highly efficient transduction of human plasmacytoid dendritic cells without phenotypic and functional maturation.

Authors:  Philippe Veron; Sylvie Boutin; Samia Martin; Laurence Chaperot; Joel Plumas; Jean Davoust; Carole Masurier
Journal:  J Transl Med       Date:  2009-01-27       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.